AAAAAA

   
Results: 1-25 | 26-50 | 51-58
Results: 26-50/58
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study, AIDS, 14(9), 2000, pp. F103-F110
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir
Authors: van Praag, RME Weverling, GJ Portegies, P Jurriaans, S Zhou, XJ Turner-Foisy, ML Sommadossi, JP Burger, DM Lange, JMA Hoetelmans, RMW Prins, JM
Citation: Rme. Van Praag et al., Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14(9), 2000, pp. 1187-1194
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Lange, JMA Danner, SA Foudraine, NA Kwakkelstein, MO Reiss, P Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals, AIDS, 14(8), 2000, pp. F77-F82
Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
Authors: Fraser, C Ferguson, NM Ghani, AC Prins, JM Lange, JMA Goudsmit, J Anderson, RM de Wolf, F
Citation: C. Fraser et al., Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs, AIDS, 14(6), 2000, pp. 659-669
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection
Authors: Putter, H Prins, JM Jurriaans, S Roos, M Ferguson, NM van Praag, R van der Hoek, L Schuitemaker, H Anderson, RM Goudsmit, J Lange, JMA de Wolf, F
Citation: H. Putter et al., Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection, AIDS, 14(18), 2000, pp. 2831-2839
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
Authors: den Brinker, M Wit, FWNM Wertheim-van Dillen, PME Jurriaans, S Weel, J van Leeuwen, R Pakker, NG Reiss, P Danner, SA Weverling, GJ Lange, JMA
Citation: M. Den Brinker et al., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14(18), 2000, pp. 2895-2902
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study
Authors: Burger, DM Hugen, PWH van der Ende, ME van Wijngaarden, P Aarnoutse, RE Reiss, P Lange, JMA
Citation: Dm. Burger et al., Once-daily indinavir plus ritonavir: preliminary results of the PIPO study, AIDS, 14(16), 2000, pp. 2621-2623
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001)
Authors: Kroon, EDMB Ungsedhapand, C Ruxrungtham, K Chuenyam, M Ubolyam, S Newell, ME van Leeuwen, R Kunanusont, C Buranapraditkul, S Sirivichayakul, S Lange, JMA Cooper, DA Phanuphak, P
Citation: Edmb. Kroon et al., A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001), AIDS, 14(10), 2000, pp. 1349-1356
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients
Authors: Ruxrungtham, K Kroon, EDMB Ungsedhapand, C Teeratakulpisarn, S Ubolyam, S Buranapraditkun, S van Leeuwen, R Weverling, GJ Kunanusont, C Lange, JMA Cooper, DA Phanuphak, P
Citation: K. Ruxrungtham et al., A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients, AIDS, 14(10), 2000, pp. 1375-1382
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study
Authors: Reijers, MHE Weigel, HM Hart, AAM Ten Kate, RW Mulder, JW Reiss, P Schuitemaker, H Hoetelmans, RMW Weverling, GJ Lange, JMA
Citation: Mhe. Reijers et al., Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study, AIDS, 14(1), 2000, pp. 59-68
Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine
Authors: Enting, RH Foudraine, NA Lange, JMA Jurriaans, S van der Poll, T Weverling, GJ Portegies, P
Citation: Rh. Enting et al., Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine, J NEUROIMM, 102(2), 2000, pp. 216-221
Quality of life in maintenance vs prolonged induction therapy for HIV
Authors: Nieuwkerk, PT Reijers, MHE Weigel, HM Lange, JMA Sprangers, MAG
Citation: Pt. Nieuwkerk et al., Quality of life in maintenance vs prolonged induction therapy for HIV, J AM MED A, 284(2), 2000, pp. 178-179
Value of different assays for detection of human cytomegalovirus (HCMV) inpredicting the development of HCMV disease in human immunodeficiency virus-infected patients
Authors: Blank, BSN Meenhorst, PL Mulder, JW Weverling, GJ Putter, H Pauw, W van Dijk, WC Smits, P Lie-A-Ling, S Reiss, P Lange, JMA
Citation: Bsn. Blank et al., Value of different assays for detection of human cytomegalovirus (HCMV) inpredicting the development of HCMV disease in human immunodeficiency virus-infected patients, J CLIN MICR, 38(2), 2000, pp. 563-569
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
Authors: Rizzardi, GP De Boer, RJ Hoover, S Tambussi, G Chapuis, A Halkic, N Bart, PA Miller, V Staszewski, S Notermans, DW Perrin, L Fox, CH Lange, JMA Lazzarin, A Pantaleo, G
Citation: Gp. Rizzardi et al., Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA, J CLIN INV, 105(6), 2000, pp. 777-782
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy
Authors: Clark, DR Repping, S Pakker, NG Prins, JM Notermans, DW Wit, FWNM Reiss, P Danner, SA Coutinho, RA Lange, JMA Miedema, F
Citation: Dr. Clark et al., T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy, BLOOD, 96(1), 2000, pp. 242-249
Anti-retroviral therapy and resistance to anti-retroviral drugs
Authors: Lange, JMA Montaner, JSG
Citation: Jma. Lange et Jsg. Montaner, Anti-retroviral therapy and resistance to anti-retroviral drugs, IMMUNOL MED, 28, 2000, pp. 221-242
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
Authors: Veldkamp, AI van Heeswijk, RPG Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Ai. Veldkamp et al., Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection, J CHROMAT B, 734(1), 1999, pp. 55-61
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
Authors: Veldkamp, AI van Heeswijk, RPG Hoetelmans, RMW Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH
Citation: Ai. Veldkamp et al., Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection, J CHROMAT B, 727(1-2), 1999, pp. 151-157
Retroviruses & opportunistic infections '99
Authors: Lange, JMA Richman, DD
Citation: Jma. Lange et Dd. Richman, Retroviruses & opportunistic infections '99, ANTIVIR TH, 4(1), 1999, pp. 5-6
Ongoing HIV dissemination during HAART
Authors: Grossman, Z Polis, M Feinberg, MB Grossman, Z Levi, I Jankelevich, S Yarchoan, R Boon, J de Wolf, F Lange, JMA Goudsmit, J Dimitrov, DS Paul, WE
Citation: Z. Grossman et al., Ongoing HIV dissemination during HAART, NAT MED, 5(10), 1999, pp. 1099-1104
Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients
Authors: Foudraine, NA Hovenkamp, E Notermans, DW Meenhorst, PL Klein, MR Lange, JMA Miedema, F Reiss, P
Citation: Na. Foudraine et al., Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients, AIDS, 13(2), 1999, pp. 177-184
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
Authors: Pakker, NG Kroon, EDMB Roos, MTL Otto, SA Hall, D Wit, FWNM Hamann, D van der Ende, ME Claessen, FAP Kauffmann, RH Koopmans, PP Kroon, FP ten Napel, CHH Sprenger, HG Weigel, HM Montaner, JSG Lange, JMA Reiss, P Schellekens, PTA Miedema, F
Citation: Ng. Pakker et al., Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy, AIDS, 13(2), 1999, pp. 203-212
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients
Authors: Blank, BSN Meenhorst, PL Weverling, GJ Stout-Zonneveld, AAM Pauw, W Mulder, JW van Dijk, WC Smits, P Lange, JMA
Citation: Bsn. Blank et al., Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients, AIDS, 13(18), 1999, pp. 2533-2539
Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
Authors: Prins, JM Jurriaans, S van Praag, RME Blaak, H van Rij, R Schellekens, PTA ten Berge, IJM Yong, SL Fox, CH Roos, MTL de Wolf, F Goudsmit, J Schuitemaker, H Lange, JMA
Citation: Jm. Prins et al., Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS, 13(17), 1999, pp. 2405-2410
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Hoetelmans, RMW Mulder, JW Schreij, G Hsu, A Lange, JMA Beijnen, JH Meenhorst, PL
Citation: Rpg. Van Heeswijk et al., The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals, AIDS, 13(14), 1999, pp. F95-F99
Risultati: 1-25 | 26-50 | 51-58